Novo Nordisk A/S received European Patent Office publication EP3793646A1 for a drug delivery assembly incorporating information capture technology, classified under IPC A61M 5/24. The patent application was filed by the Danish pharmaceutical company and covers medical device technology for drug delivery with integrated data capture capabilities.\n\nThis patent publication does not impose compliance obligations on third parties. Companies developing similar drug delivery technologies should conduct freedom-to-operate analyses to assess potential infringement risks. Intellectual property professionals should monitor this patent for competitive intelligence purposes.